{"id":34926,"date":"2025-06-09T16:12:45","date_gmt":"2025-06-09T08:12:45","guid":{"rendered":"https:\/\/flcube.com\/?p=34926"},"modified":"2025-06-09T16:12:46","modified_gmt":"2025-06-09T08:12:46","slug":"bayers-confidence-study-shows-kerendia-and-empagliflozin-reduce-uacr-in-t2d-ckd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34926","title":{"rendered":"Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD"},"content":{"rendered":"\n

German pharmaceutical giant Bayer AG (ETR: BAYN<\/a>) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.<\/p>\n\n\n\n

Study Results<\/strong>
The CONFIDENCE study revealed that dual therapy with finerenone and empagliflozin achieved a 52% reduction in UACR from baseline to day 180. This represents a 29% and 32% greater relative reduction compared to finerenone or empagliflozin monotherapy, respectively. Notably, a UACR reduction exceeding 30%, the threshold recommended by the American Diabetes Association (ADA) for slowing CKD progression, was observed within just 14 days of combined treatment initiation.<\/p>\n\n\n\n

Patient Outcomes and Safety<\/strong>
Nearly three-quarters of patients achieved a \u226530% UACR reduction from baseline, which is 20% more than with either monotherapy. The safety profile of the combination therapy was consistent with the individual drug profiles, and treatment benefits were observed across all prespecified subgroups, including patients with high comorbidity burdens.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,…<\/p>\n","protected":false},"author":1,"featured_media":34927,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,17,967],"class_list":["post-34926","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-clinical-trial-results","tag-etr-bayn"],"yoast_head":"\nBayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34926\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34926\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-09T08:12:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-09T08:12:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD\",\"datePublished\":\"2025-06-09T08:12:45+00:00\",\"dateModified\":\"2025-06-09T08:12:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0907.webp\",\"keywords\":[\"Bayer\",\"Clinical trial results\",\"ETR: BAYN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34926#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34926\",\"name\":\"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0907.webp\",\"datePublished\":\"2025-06-09T08:12:45+00:00\",\"dateModified\":\"2025-06-09T08:12:46+00:00\",\"description\":\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34926\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0907.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34926#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34926","og_locale":"en_US","og_type":"article","og_title":"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD","og_description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.","og_url":"https:\/\/flcube.com\/?p=34926","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-09T08:12:45+00:00","article_modified_time":"2025-06-09T08:12:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34926#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34926"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD","datePublished":"2025-06-09T08:12:45+00:00","dateModified":"2025-06-09T08:12:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34926"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34926#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","keywords":["Bayer","Clinical trial results","ETR: BAYN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34926#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34926","url":"https:\/\/flcube.com\/?p=34926","name":"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34926#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34926#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","datePublished":"2025-06-09T08:12:45+00:00","dateModified":"2025-06-09T08:12:46+00:00","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study, which demonstrated that the combination of Kerendia (finerenone) and the SGLT-2 inhibitor empagliflozin significantly reduces the urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD). This reduction was observed compared to either drug used alone.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34926#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34926"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34926#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","width":1080,"height":608,"caption":"Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34926#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34926"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34926\/revisions"}],"predecessor-version":[{"id":34928,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34926\/revisions\/34928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34927"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}